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Abstract: The majority of patients with acute myeloid leukemia (AML) are elderly and 
have a poor prognosis despite induction therapy. Decitabine, a DNA-hypomethylating agent 
that induces differentiation and apoptosis of leukemic cells, is a well-tolerated alternative to 
 aggressive chemotherapy. It is currently FDA-approved for myelodysplastic syndrome, including 
patients with 20%–30% bone marrow blasts. Recent clinical attention has focused on evaluating 
 decitabine as frontline therapy for untreated high-risk elderly AML patients. A large randomized 
international phase III study comparing decitabine to supportive care and cytarabine in elderly 
AML patients demonstrated significantly improved complete remission rates, but the survival 
difference did not reach significance. Due to this, decitabine did not achieve FDA approval 
for AML, but continues to be used off-label. Current research is focused on further defining 
subgroups of elderly AML patients who may derive greater benefit from decitabine therapy 
and combining it with other low-intensity active agents for AML.
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Introduction
The majority of the approximately 14,500 individuals diagnosed with acute myeloid 
leukemia (AML) each year in the US are over age 60 years, and a third are over age 
75 years.1 Unfortunately, advanced age is one of the most adverse prognostic factors 
in AML, in part because older patients have difficulty tolerating chemotherapy due 
to comorbidities, concomitant end-organ dysfunction, and poor performance status. 
However, the biology of the disease in the elderly also contributes to poor outcomes. 
AML in older patients can be secondary to overt or unrecognized myelodysplastic 
syndromes (MDS), which tends to be less chemoresponsive. AML in the elderly is 
also associated with complex and monosomal karyotypes with adverse cytogenetics,2–6 
fewer favorable mutations such as NPM1,5 and a multidrug-resistant phenotype.6 Even 
within each molecular risk group, older patients tend to have a more chemoresistant 
disease, the precise mechanisms for which are unknown.
Due to the high morbidity and relatively low efficacy associated with standard 
induction chemotherapy for elderly patients, there has been considerable interest in the 
hypomethylating agents 5-azacitadine and decitabine as frontline therapy. Both drugs 
were originally developed as cytarabine analogues to be used at high doses as antime-
tabolites, until their ability to target epigenetic changes that  contribute to leukemogenesis 
was discovered. While their precise mechanism of action is unclear, it is thought that 
by reversing methylation-induced gene expression and perhaps through direct cyto-
toxicity, both agents can reactivate tumor-suppressor genes and promote apoptosis.7,8 





They are currently FDA-approved for MDS, after trials 
demonstrated complete and partial remissions lasting several 
months when compared to supportive therapy, with a toler-
able toxicity profile.9–11 This article addresses the clinical 
evidence, toxicity, and potential role of decitabine in previ-
ously untreated elderly patients with AML.
Treatment options for elderly  
AML patients
There are several distinct therapy pathways for elderly 
adults diagnosed with AML. For patients age 60–65 years 
with good performance status and favorable cytogenet-
ics, induction with the 7+3 regimen of cytarabine and an 
anthracycline (daunorubicin, idarubicin, or mitoxantrone) 
offers the possibility of durable disease control and may be 
the best treatment option. In fact, a study by Löwenberg et al 
suggested that these patients may benefit from higher doses 
of anthracyclines (90 mg/m2/day instead of 45 mg/m2/day of 
daunorubicin) with reported complete remission (CR) rates of 
64% versus 54%.12 However, the benefits of the higher-dose 
anthracycline were limited to patients under 65 years old. 
Responses can be consolidated with additional cycles of 
cytarabine or reduced-intensity conditioning allogeneic stem 
cell transplantation.
While remission rates of 40%–50% with the 7+3 regimen 
have been noted in elderly patients in clinical trials, median 
survival is still dismal at 7–12 months, with a 7% 2-year sur-
vival in some subgroups.13–15 Induction chemotherapy is also 
associated with significant upfront morbidity, with 4-week 
mortality of 15%–30% in select elderly populations.13,14,16 
In addition, many elderly patients are unable to undergo 
allogeneic stem cell transplantation due to poor performance 
status, comorbidities, and older sibling age, leading to trans-
plant rates of 5% in one prospective feasibility study.17 For 
elderly patients with intermediate- or high-risk cytogenetics 
or unfavorable molecular markers who are not candidates 
for transplantation, the limited curative potential and high 
toxicity of standard chemotherapy has led many patients and 
oncologists to pursue alternative options. For many years, the 
primary option was supportive care and referral to a hospice. 
This path was chosen by over two-thirds of older adults with 
AML during the 1990s and was associated with a median 
survival of only 1 month.18
A number of intermediate-intensity therapy regimens have 
now been investigated for the large subset of elderly patients 
over 65 years old who are unlikely to benefit from aggres-
sive induction therapy but who desire treatment. While not 
curative, these agents offer the promise of remission and/or 
stabilization of counts, allowing additional months of quality 
life outside the hospital. Low-dose cytarabine (LDAC) has 
been established as the prototype of this middle route after a 
randomized study by Burnett et al showed higher rates of CR 
(18% versus 1%) and overall survival compared to supportive 
care in a population of elderly adults who were not candidates 
for conventional therapy.19 However, overall survival was 
only 4 months for the LDAC cohort, a modest improve-
ment over the 3 months seen in the hydroxyurea group. 
 Additionally, for patients with adverse cytogenetics, no benefit 
in remission or survival was noted. Gemtuzumab  ozogamicin 
had shown some promise in elderly patients,20 but it was 
withdrawn from the market in 2010 after a postmarketing 
confirmatory phase III trial was terminated for lack of defini-
tive benefit and enhanced toxicity.21 Aside from clinical trials, 
the current National Comprehensive Cancer Care guidelines 
suggest  clofarabine, 5-azacitidine, and decitabine as alterative 
options for this population of patients.22  Clofarabine23 and 
5-azacitadine24 have been reviewed elsewhere.
Decitabine
Decitabine (5-aza-2′-deoxycytidine or 5-Aza-Cdr) is a cyto-
sine analogue that was first synthesized in the early 1960s 
by Pliml and Sorm and is currently marketed as Dacogen® 
by Eisai (Tokyo, Japan). It differs from deoxycytidine by 
the substitution of nitrogen for carbon at the 5-position 
of the pyrimidine ring (Figure 1). It was noted to have an 
antileukemic effect in cell lines, with more potency in vitro 
than cytarabine.25 Initially, its cytotoxicity was attributed to 
its ability to impair DNA synthesis and cause DNA damage 
similar to other antimetabolites. Early clinical experience 
therefore utilized this drug in high doses (up to 1,000 mg/m2 
per cycle) alone and in combination with anthracyclines, 
with considerable hematological and nonhematological 
toxicity.26,27
Preclinical studies in the 1980s, however, demonstrated 
that at low doses, decitabine induced differentiation by 
reversing DNA methylation-induced gene silencing.28 Once 
inside a cell, decitabine is phosphorylated and activated by 
the enzyme deoxycytidine kinase to its triphosphate form 
aza-dCTP.29,30 It then competes with and replaces cytosine 
in the CpG (cytosine–guanosine dinucleotide) islands that 
occur in clusters in promoter regions. During subsequent cell 
divisions, aza-dCTP inhibits methylation of the promoter by 
forming a covalent bond with the enzyme DNA methyltrans-
ferase (DNMT), and thereby traps and contributes to degrada-
tion of the enzyme.29,31 Since methylation-induced aberrant 
transcriptional silencing of tumor-suppressor genes has been 
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implicated in the pathogenesis of a variety of human cancers, 
including MDS and AML,32–34 this led to clinical interest in 
using low-dose decitabine in these malignancies.
Phase III studies in MDS
Two phase III studies of decitabine in the MDS population 
warrant mention in this review, since they included patients 
with 20%–30% bone marrow blasts who were initially 
classified as the refractory anemia with excess blasts in 
transformation subset of MDS. This group was reclassified 
as AML by the WHO criterion in 2002. The first study by 
Kantarjian et al in 2006 randomized 170 patients with high-
risk MDS to supportive care with transfusions or decitabine 
at a dose of 15 mg/m2 intravenously (IV) every 8 hours for 
3 days (total dose per cycle of 135 mg/m2) every 6 weeks.11 
Thirty-one of the 170 patients in this study (18%) met the 
WHO criterion for AML. Patients in the decitabine arm had a 
17% response rate (9% CR), compared to no responses noted 
in the supportive-care group. An additional 13% of patients 
on decitabine achieved some hematological response. 
Responses were durable, lasting a median of 10.3 months, and 
were associated with transfusion independence. Decitabine 
therapy was also associated with a trend towards longer time 
to AML progression or death (median 12.1 vs 7.8 months), 
but this did not reach statistical significance (P=0.16). 
Among the patients with .20% bone marrow blasts, three 
of the 17 patients randomized to the decitabine arm (19%) 
achieved either a complete or partial response. Decitabine 
was largely well tolerated, with hematological toxicities 
being the most common. Based on these data, decitabine 
gained FDA approval for MDS.
A second randomized multicenter phase III European 
study published in 2011 compared decitabine to supportive 
care in 233 patients with MDS, including 75 patients (32%) 
with 20%–30% bone marrow blasts.35 Decitabine was given 
at the same dose (15 mg/m2 IV three times a day for 3 days 
as part of a 6-week cycle). Response rates were similar 
to the previous study, with 13% of patients on decitabine 
achieving CR, 6% achieving partial remission, and 15% 
achieving hematological improvement. Again, although 
there was a trend towards improved overall survival (median 
of 10.1 months versus 8.5 months, P=0.38) and AML-free 
survival (median of 8.8 versus 6.1 months, P=0.24), it did 
not reach statistical significance. However, progression-free 
survival (6.4 months versus 3.0 months) was significantly 
different (P=0.004). Decitabine was also associated with 
improvements in patient-reported quality-of-life measures. 
Again, the primary toxicity remained hematological, with 
25% of patients on the decitabine arm experiencing grade 
3/4 febrile neutropenia compared to 7% on the supportive-
care arm.
Phase I studies in AML
Three phase I studies of low-dose decitabine in patients 
with leukemia examined safety and response to different 
decitabine regimens, including combination therapy with 
other low-intensity agents. The majority of patients in these 
studies were elderly, and most had relapsed AML. They set 
the stage for the phase II and III studies described further, 
and are summarized in Table 1.
The first phase I study, by Issa et al in 2004, examined 
four different regimens of decitabine in 50 patients with 
hematological malignancies, of whom nearly three-quarters 
carried a diagnosis of AML.36 Patients were treated with 5, 10, 
15, or 20 mg/m2 of decitabine daily for 10–20 days. Overall, 
response was noted in 32% of patients, with CR in 18%. 
Among the AML patients, 14% achieved CR and 8% had 
CR with incomplete platelet recovery (CRp). The 15 mg/m2 
10-day dosing was noted to be optimal, with responses 
observed in 65% of patients. Treatment was well tolerated, 




































































Figure 1 Comparison of the chemical structures of decitabine (5-aza-2′-deoxycytidine) and cytarabine with that of the nucleotide deoxycytidine.





A second phase I/II study by Garcia-Manero et al 
treated 54 AML and MDS patients with a decitabine dose 
of 15 mg/m2/day for 10 days, in combination with the 
 histone deacetylase inhibitor valproic acid.37 Valproic acid 
was escalated to 50 mg/kg/day, with an acceptable level of 
neurotoxicity. The majority of the patients had AML (48 of 
54), with a median age of 60 years. Overall, 22% of patients 
had a response, including ten with CR and two with CRp. 
Notably, 50% of the previously untreated AML patients had a 
response. Overall survival was 6 months, but median survival 
was as high as 15.3 months in the responders. The primary 
nonhematological toxicity was anorexia and confusion, with 
the latter primarily attributed to the valproic acid.
A third phase I study by Blum et al also examined decit-
abine in combination with valproic acid in AML patients.38 
Twenty-five patients (twelve untreated, 13 relapsed) with 
AML with a median age of 70 years were enrolled. Two 
doses of decitabine were administered (15 mg/m2/day and 
20 mg/m2/day) for 10 days, and the higher dose was defined 
as the optimum biological dose, as it induced higher rates 
of reexpression of ER and P15 (genes methylated in AML). 
Three different valproic acid dosing regimens were then 
combined with the 20 mg/m2 dose of decitabine. Confusion 
again was the primary toxicity observed with valproic acid, 
especially with doses above 20 mg/kg/day. The overall 
response rate was 44% in the intention-to-treat group and 
52% (eleven of 21) in assessable patients. The addition of 
valproic acid did not appear to confer any additional benefit. 
The authors concluded that given valproic acid’s narrow 
therapeutic index and toxicity, decitabine alone or in com-
bination with alternative histone-deacetylating agents should 
be the focus of future studies.
Phase II studies in AML
Three phase II studies established decitabine’s activity 
in elderly AML patients. In a multicenter study, Cashen 
et al treated 55 newly diagnosed older AML patients with 
 intermediate- or poor-risk cytogenetics with decitabine 
20 mg/m2/day for 5 days, repeated on a 4-week cycle.39 The 
5-day decitabine regimen was drawn from studies that had 
found this outpatient schedule to be effective and well toler-
ated in MDS patients.40,41 The study population was a high-
risk group, with a median age of 74 years, 42% secondary 
AML, and median baseline bone marrow blast percentage of 
50%. After a median of three cycles of decitabine, the overall 
response rate was 25% and an additional 29% had stable 
disease. The majority of the responders achieved morphologi-
cal CR (13 of 14), with one patient achieving CR with incom-
plete count recovery (CRi). Response rates were preserved 
in patients with poor-risk cytogenetics, a subgroup that has 
historically derived limited benefit with other agents such as 
LDAC.19 While a majority of the study population did not have 
proliferative AML (median white blood cell count 2.7), it was 
notable that only one (7%) of 14 patients with a peripheral 
blast count over 1,000/µL achieved CR. Among patients with 
a cytogenetic abnormality at baseline, five of 25 achieved 
cytogenetic remission. The time to achieve CR was 4.5 cycles, 
favoring differentiation rather than cytotoxicity as the primary 
mechanism of action and indicating that persistence with the 
medication is needed if the drug is tolerated and the disease is 
stable. Median survival was 7.7 months for the full cohort, but 
was 14 months for the responders. The drug was fairly well 
tolerated, with myelosuppression, febrile neutropenia (29%), 
and fatigue as the major toxicities and a 30-day mortality of 
7%. This promising response rate and toxicity profile set the 
Table 1 Summary of clinical trials examining low-dose decitabine in acute myeloid leukemia (AML)




CR* (%) Median survival 
(months)
issa et al36 i varied, with 15 mg/m2 daily for 10 days  
noted to be optimal
37 60 21.6 NR
Garcia-Manero et al37,** i/ii 15 mg/m2 daily for 10 days every 4 weeks 48 60 18.8 NR
Blum et al38,** i varied, with 20 mg/m2 daily for 10 days  
every 4 weeks noted to be optimal
25 70 32.0 NR
Cashen et al39 ii 20 mg/m2 daily for 5 days every 4 weeks 55 74 25.4 7.7
Blum et al42 ii 20 mg/m2 daily for 10 days every 4 weeks 53 74 64.2 12.7
Lübbert et al43 ii 15 mg/m2 three times daily for 3 days  
every 6 weeks
227 72 13.2 5.5
Kantarjian et al44 iii 20 mg/m2 for 5 days every 4 weeks  
vs LDAC or supportive care
485 (242 with 
decitabine)
73 17.8 vs 7.8  
(P=0.001)
7.7 vs 5 (P=0.11)
Notes: *CR rate includes patients with complete remission with incomplete count recovery, except for Lübbert (2010), where only CR was included. CR with incomplete 
count recovery in this study was combined with partial remission. **Some patients were treated with valproic acid in addition to decitabine.
Abbreviations: CR, complete remission; NR, not reported; LDAC, low-dose cytarabine.
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stage for the use of this decitabine dose in the phase III study 
described later.
A single-center phase II trial by Blum et al increased the 
first-cycle dose of decitabine to 20 mg/m2/day for 10 days, 
with cycle length reduced to 5 days if response was observed.42 
Fifty-three older patients with newly diagnosed AML were 
treated. In contrast to the Cashen et al study,39 this study 
population included patients with good-risk prognostic fac-
tors (19% of enrollees). The median age was 74 years, and 
36% of patients had secondary AML. After treatment with 
a median of four cycles of decitabine, the response rate was 
64% (34 of 53), with 49% CR and 15% CRi. The response 
rate was similarly high across all cytogenetic subgroups, 
and was even observed in patients with high circulating 
blasts, where the response was 50% for patients with a white 
blood cell count .50,000. Interestingly, in eleven patients 
with monosomy 7 or deletion of 7q, the response rate was 
 remarkable – 91%. Median survival was 12.7 months, and 
disease-free survival for patients in CR was 10.6 months. 
The primary toxicity remained myelosuppression. The higher 
dose of decitabine (10-day cycle), along with longer exposure 
to the drug (four cycles), resulted in higher rates of febrile 
neutropenia compared to prior studies (68%), but overall 
decitabine was well tolerated, with only one death (2%) within 
30 days of therapy. The authors correlated response with 
pretreatment levels of microRNA29b (miR29b), an miRNA 
that specifically inhibits DNA methyltransferase expression. 
Patients who responded to decitabine tended to have higher 
levels of miR29b (P=0.02), indicating that it could potentially 
be used as a predictive marker for response.
A third large phase II study, by Lübbert et al, treated 227 
elderly AML patients at nine centers in Europe, with an MDS 
dosing schedule of decitabine at 15 mg/m2 every 8 hours for 
3 days as part of a 6-week cycle.43 Patients who had stable 
disease or antileukemic effect after cycle 1 were given all-
trans retinoic acid (ATRA) at the next cycle, to determine if 
hypomethylation promoted ATRA susceptibility even in the 
absence of PML–RARA fusion (based on preclinical studies). 
The study population had poor prognostic indicators, with a 
median age of 72 years, 51% secondary AML, 32% adverse 
cytogenetics, and median bone marrow blasts of 56%. After 
receiving a median of two cycles, objective response was 
achieved in 26% (59 patients), with CR in 30 patients (13%) 
and partial remission (5%–25% bone marrow blasts or CRi) 
in 29 additional participants. A further 26.4% of patients 
responded with “antileukemic effect,” defined as 25% 
reduction in blasts without meeting the criterion for partial 
remission, and another 25% had stable disease. Response 
rates were similar in patients with adverse cytogenetics 
(29%) and those with the very poor-risk monosomal karyo-
type (37%). Median survival was 5.5 months. The inclusion 
of ATRA with cycle 2 did not prolong survival in patients. 
Decitabine was again well tolerated, with 33.5% of patients 
experiencing grade 3 or 4 toxicity. Mortality after the first 
cycle was 12.8%. While the CR rate in this study was lower 
than previous ones, at 13%, this may be reflective of the 
study design, which called for application of four courses 
of therapy and then optional maintenance therapy without 
systematic recording of improvement in response rate while 
on maintenance. The authors concluded that decitabine was 
well tolerated, with encouraging responses noted in patients 
with poor-risk cytogenetics.
Phase III study in AML
The phase III randomized trial examining outcomes with 
decitabine in elderly AML patients was an open-label study 
of 485 patients in 15 countries randomized in a 1:1 fashion to 
decitabine or their treatment choice (TC) of either LDAC or 
supportive care.44 The majority of the patients in the TC arm 
received LDAC therapy (218 of the 243 patients) at a dose 
of 20 mg/m2 daily subcutaneously for 10 days as a 4-week 
cycle. Notably, the daily LDAC dosing was lower than 
prior studies, including those by Burnett et al (which used a 
twice-daily regimen),19 with the reduction done for dosing 
convenience. The decitabine dose was the same as that used 
in the phase II study by Cashen et al,39 at 20 mg/m2/day IV 
for 5 days as a 4-week cycle. The population was high-risk, 
with an average age of 73 years, median bone marrow blast 
count of 46%, and 35.3% with secondary AML. Patients with 
favorable cytogenetics were excluded. The primary end point 
was overall survival, which was prospectively specified to 
occur at 385 deaths (80%), and the study was powered to 
detect a 25% reduction in mortality. Secondary end points 
included the combination of CR and CRp and safety.
While there was a trend towards improved survival with 
decitabine (7.7- versus 5.0-month median survival) at the 
prospectively defined time point, the hazard ratio of 0.85 was 
not statistically significant (P=0.108). However, statistical 
significance was achieved in a follow-up ad hoc analysis per-
formed 1 year later, when 92% of deaths had occurred. At that 
time point, the median survival remained the same, and the 
hazard ratio was 0.82 (P=0.037). Also, by censoring patients 
who received subsequent antileukemic therapy (37.6% 
patients in the decitabine arm and 44.4% in the TC arm), 





overall survival was again significant (8.5- versus 5.3-month 
median survival, P=0.044).
Multivariate analysis of survival demonstrated decit-
abine superiority in patients over 75 years old, those with 
an Eastern Cooperative Oncology Group performance status 
of 2, and those with over 30% marrow blasts. Interestingly, 
no difference between decitabine and LDAC was noted in 
the subgroup with 20%–30% marrow blasts. This group 
did derive benefit from decitabine in the phase III studies 
of decitabine in MDS,11,34,35 but the control group in those 
studies was supportive care alone, which may account for 
the discrepancy in results.
Regarding the secondary end points, patients on decit-
abine had significantly improved rates of CR and CRp (17.8% 
vs 7.8% in the TC group) at the prespecified cutoff, with an 
odds ratio of 2.5 (1.4–4.8, P=0.001). The safety profile of 
decitabine was similar to LDAC, with the majority of patients 
in both arms experiencing some grade 3 or 4 toxicity while 
taking the study drug. The primary toxicity was hematologic, 
with a higher incidence of thrombocytopenia (40% vs 32%), 
anemia (34% vs 25%), and neutropenia (32% vs 18%) in the 
decitabine arm. Infectious complications were also slightly 
higher in the decitabine group, with febrile neutropenia 
(32% vs 22%) and pneumonia (21% vs 18%) being the two 
most common. However, the authors noted that patients in 
the decitabine arm were exposed to the study medication 
longer than the LDAC group (4.4 months vs 2.4 months), 
which likely contributed to greater reporting of adverse 
events. Discontinuation of the study drug was similar for 
decitabine (6%) and cytarabine (8%). The authors concluded 
that decitabine was at least as well tolerated as LDAC, with 
no major differences in safety.
While this phase III study demonstrated decitabine to be 
an effective alternative to LDAC for high-risk elderly patients 
with AML, its results have been fraught with  controversy. 
Based on the same trial data, the FDA Oncological Drug 
Advisory Committee (ODAC) voted against approving 
decitabine for the indication of AML in elderly patients, but 
the European Medicines Agency Committee for Medicinal 
Products for Human Use approved it. The controversy stems 
largely from difficulty in assigning superiority to decitabine 
when the survival differences at the prospectively specified 
end point did not reach significance. While mature data 
with more deaths included did show significantly improved 
survival with decitabine, the fact that it was an unplanned 
analysis led to concern for a false-positive result.45 The FDA 
panel also noted that the CR rate with LDAC (8.4%) was 
lower than prior studies that had reported 15%–20%.13,19,44,45,46 
While comparisons across trials are fraught with bias due to 
differences in patient characteristics, the fact that a lower 
dose of cytarabine was used does raise the possibility that 
suboptimal cytarabine dosing in the control arm contributed 
to this lower CR rate. Finally the ODAC panel also expressed 
concern that in the Western European study population 
(where LDAC is more frequently used), the survival trend 
favored LDAC versus decitabine (median survival 12.5 
versus 9 months, P=0.91).45 However the authors refuted 
the merits of this argument by noting that the patients in the 
decitabine arm in Europe had worse baseline characteristics 
and many patients in the TC arm in Europe subsequently 
received further therapy with hypomethylating agents, mak-
ing it difficult to derive any conclusions from this subgroup 
analysis.47
Prior studies have suggested that certain subgroups of 
elderly AML patients benefit more from hypomethylating 
agents. The phase II data by Cashen et al39 and data from 
azacitidine46 have suggested that hypomethylating agents 
may be particularly beneficial in hypoproliferative AML. 
However, the data from the phase III study did not analyze 
peripheral blast count as an independent variable. Additional 
studies have suggested that decitabine may also confer greater 
benefit to subgroups with specific molecular characteristics. 
Monosomal karyotype patients, who have worse outcomes 
with standard cytotoxic chemotherapy,48 had impressive 
response rates to decitabine in phase II AML studies42,43 
and to azacitidine in MDS.49,50 However, outcome based on 
karyotype was not provided in the phase III study either, and 
could be a subject of further investigation.
Decitabine as a bridge  
to transplant in AML patients
A single-center study has explored decitabine as a bridge to 
reduced-intensity allogeneic transplant for elderly patients 
with a good performance status.51,52 Traditionally, standard 
induction chemotherapy has been used to achieve CR 
prior to transplant. Lübbert et al tested decitabine instead, 
with the hypothesis that the drug’s milder toxicity would 
reduce up-front mortality and may in fact enhance the graft-
versus-leukemia effect by upregulating human leukocyte-
antigen expression.51 They reported their experience with 
15 consecutive elderly patients (nine with AML and six 
with MDS), with a median age of 69 years, treated with 
decitabine at 15 mg/m2 every 8 hours for 3 days as part of 
a 6-week cycle. After a median of five cycles of decitabine, 
five patients achieved CR. Allografting was performed after 
conditioning with a reduced-intensity regimen of fludarabine, 
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carmustine, and melphalan. The median blast percentage for 
study  population was 24% both at the start of induction and 
at the time of transplant. After transplant, one patient died 
of infection before engraftment, but eight of ten patients for 
whom data were available had full donor chimerism at 30 and 
100 days after transplant. The rates of graft-versus-host dis-
ease were not higher than expected. While median duration 
of CR after transplant was only 5 months, survival at 1 year 
was 47%, at 2 years was 30%, and three patients continued 
to be alive over 5 years after their transplant at the time of 
publication of their update.52 While this was only a small 
single-center study, it supports further investigation of decit-
abine induction chemotherapy as a bridge to transplant.
Conclusion and future directions
The hypomethylating agent decitabine at low doses promotes 
cellular differentiation by reversing epigenetic suppression 
of genes, and has shown efficacy in producing remissions 
lasting several months in a subset of elderly patients with 
MDS and AML. It can be given as outpatient therapy daily 
for 5–10 days per cycle. It is relatively well tolerated in the 
elderly population, with myelosuppression and febrile neu-
tropenia as the primary toxicity. Multiple cycles of decitabine 
may be needed to achieve remission, and therefore treatment 
should be continued as long as the disease is stable. A recent 
phase III study demonstrated higher rates of complete remis-
sion with decitabine therapy compared to low-dose cytarabine 
in elderly AML patients, but the survival difference failed to 
reach significance.44,45 
At present, the role of decitabine in the treatment of 
elderly AML patients is yet to be fully defined. At this 
time, there are multiple ongoing studies to further delineate 
decitabine’s efficacy in elderly AML patients.53 Given its 
relatively mild toxicity, decitabine continues to be an attrac-
tive agent for combination therapy with other antileukemic 
agents. Phase I and II studies examining decitabine in com-
bination with low-dose cytarabine (NCT01829503), bort-
ezomib (NCT01420926), plerixafor (NCT01352650), and 
the tyrosine-kinase inhibitors midostaurin (NCT01846624) 
and sorafenib (NCT01861314) are all currently under way.53 
There continues to be interest in combining decitabine with 
newer, less toxic histone deacetylase inhibitors, such as 
AR-42 (NCT01798901), with the rationale that promoting 
histone acetylation would lead to an open chromatin configu-
ration and permit repressed gene expression synergistically, 
as has been noted in preclinical studies.54 Correlative studies 
are also ongoing to define cytogenetic and molecular charac-
teristics that predict response to decitabine (NCT01687400). 
A retrospective analysis of DNMT3A mutation status and 
decitabine response  demonstrated a response rate of 75% in 
a cohort of eight patients, but this needs further validation 
in larger studies.55 An observation from the phase II data 
that monosomal karyotype elderly AML patients may have a 
disproportionate benefit from decitabine also warrants further 
attention. An oral formulation of decitabine is also under 
investigation,56 and may provide a more convenient option 
for elderly patients. Another trial comparing a 10-day versus 
5-day decitabine regimen is also under way, given the higher 
response rates in the single-center phase II study with the 
10-day regimen (NCT01786343). Decitabine may also have 
a role as maintenance therapy or as a bridge to allogeneic 
stem cell transplant.51,52
In conclusion, elderly AML patients with  intermediate- 
and poor-risk cytogenetics continue to have a very poor 
prognosis. Standard induction chemotherapy has a high 
up-front mortality in this population, with a high likelihood 
of relapse even if remission is achieved. Decitabine is a well-
tolerated therapeutic alternative, and recent clinical evidence 
has shown it to be effective in producing remissions lasting 
several months or disease stabilization in a subset of this 
population. Further studies are needed to define which subset 
of elderly patients is most likely to derive maximal benefit 
from single-agent decitabine therapy.
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